The U.S. Food and Drug Administration has issued an import alert and plans to test all shipments of the drug heparin before they enter the country.
Multiple batches of heparin sold by Baxter International have been been found to contain a mysterious contaminant, The Wall Street Journal reported Friday. The contaminated product was made in a Chinese plant.
Baxter told the newspaper company officials think the contaminant comes from pig intestines used to produce the popular anti-coagulant. The company said four recent deaths may have been at least partly related to reactions to its heparin.
Five manufacturers have agreed to test all shipments of heparin and its main ingredients for contamination, the newspaper said.
Copyright 2008 by United Press International
Related stories:
US Pharmacopeia announces revised heparin monographs and reference standards
Standards updated in response to public health threat associated with blood-thinning drug's adulteration with over-sulfated chondroitin
The U.S. Pharmacopeial (USP) Convention announces that revised monographs for heparin sodium and heparin calcium in the United States Pharmacopeia (USP) are now available and official on the USP Web site. The revised monographs are accompanied by two new and two updated official USP Reference Standards. These public standards allow any party—and particularly the Food and Drug Administration (FDA) and manufacturers—to test heparin sodium and calcium drug substances to assure their quality. All drug manufacturers who market heparin in the United States are required to meet these newly revised standards. The heparin monographs were updated in the interest of public health following the deaths of more than 200 people earlier this year. These deaths are suspected to have resulted from the adulteration of the blood thinner with over-sulfated chondroitin, which is derived from the chemical chondroitin and used in dietary supplements.
Undergrad has sweet success with invention of artificial Golgi
An undergraduate student at Rensselaer Polytechnic Institute has learned very quickly that a spoonful of sugar really does help the medicine go down. In fact, with his invention, the sugar may actually be the medicine.
Baxter may stay out of Heparin business
The head of Baxter International Inc. said the company has not decided whether it will resume selling the blood thinner heparin in the United States.
Researchers unravel heparin death mystery
An international team of researchers led by MIT has explained how contaminated batches of the blood-thinner heparin were able to slip past traditional safety screens and kill dozens of patients recently in the United States and Germany.
Heparin recall spreads in Europe
France, Italy and Denmark are recalling heparin after an Italian firm purchased contaminated ingredients from China, EU drug regulators said.
Chemists move closer toward developing safer, fully-synthetic form of heparin
Chemists are reporting a major advance toward developing a safer, fully-synthetic version of heparin, the widely used blood thinner now produced from pig intestines. The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic reactions among patients exposed to the drug for kidney dialysis and other conditions.
Boosting survival of insulin-cell transplants for Type 1 Diabetes
Researchers in Japan are reporting a discovery that could improve the effectiveness and expand the use of transplants of insulin-producing cells to treat diabetes. Their study is scheduled for the July 16 issue of ACS'
Bioconjugate Chemistry. Insulin-dependent, or Type 1, diabetes affects about 800,000 people in the United States.
New blood clot guidelines for pregnant women
Blood clot recommendations highlight challenges for pediatric and pre-surgery populations
New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies. Published as a supplement in the June issue of
CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and Thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an international panel of 90 experts and includes more than 700 of the most comprehensive recommendations related to the prevention, treatment, and long-term management of thrombotic disorders. The guidelines include chapters on the challenges in preventing and treating thrombosis in pregnant women and children, and on managing peri- and postoperative patients, while also reinforcing previous guidelines related to the routine use of preventive therapies, including aspirin.